Organicell Regenerative Medicine, Inc. (BPSR) es una empresa que cotiza en bolsa en el Salud sector, operando dentro de la Biotecnología industria. La empresa tiene su sede en Miami, FL, United States. El CEO actual es Albert Mitrani.
BPSR tiene fecha de IPO 2022-01-31, 18 empleados a tiempo completo, cotiza en el Other OTC.
Organicell Regenerative Medicine, Inc. processes, distributes, and supplies biologically processed cellular and tissue-based products in the United States. The company was formerly known as Biotech Products Services and Research, Inc. and changed its name to Organicell Regenerative Medicine, Inc. in June 2018. Organicell Regenerative Medicine, Inc. has an agreement with Regenerative Care Network to study potential therapeutic benefits of Zofin for patients with heart failure. Organicell Regenerative Medicine, Inc. was founded in 2011 and is headquartered in Miami, Florida.
